Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XL 784

Drug Profile

XL 784

Alternative Names: XL784

Latest Information Update: 17 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exelixis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action ADAM10 protein inhibitors; Angiogenesis inhibitors; Matrix metalloproteinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Diabetic nephropathies

Most Recent Events

  • 18 Jan 2008 GlaxoSmithKline decides not to exercise its option to license XL 784
  • 07 Nov 2007 Final results from a Phase-II clinical trial in patients with Diabetic nephropathies added to the adverse events and Diabetes therapeutic trials sections
  • 16 Oct 2007 Exelixis completes a Phase-II trial in Diabetic nephropathies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top